Arnoud van 't Hof

Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial

van Ginkel D, Bor WL, Dubois CL, Aarts HM, Rooijakkers MJ, van Bergeijk KH, Rosseel L, Veenstra L, De Backer O, Van Mieghem NM, van der Kley F, Wilgenhof A, Leonora R, Halim J, Schotborgh CE, Barbato E, Van Der Heyden JA, Frambach P, Ferdinande B, Mylotte D, Fabris E, Rensing BJ, Timmers L, Swaans MJ, Brouwer J, Nijenhuis V, Peper J, Vriesendorp PA, de Laat B, Ninivaggi M, Stragier H, Voskuil M, IJsselmuiden AJ, Hermanides RS, Agostoni P, van 't Hof A, Wykrzykowska JJ, van Royen N, Delewi R, ten Berg JM

August 22, 2023 | 10.4244/EIJ-D-23-00206

Letter: Pretreatment with unfractioned heparin in patients undergoing primary PCI: a standard of treatment together with DAPT?

Fabris E, van 't Hof A

April 24, 2023 | 10.4244/EIJ-D-22-00821

Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction

Bor WL, Zheng K, Tavenier A, Gibson CM, Granger C, Bentur O, Lobatto R, Postma S, Coller B, van 't Hof A, ten Berg JM

August 6, 2021 | 10.4244/EIJ-D-21-00287

Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial

Gargiulo G, Pasquetto G, Brugaletta S, Ferrari F, Casu G, Guiducci V, Dellavalle A, Liistro F, Mauro C, van 't Hof A, Omerovic E, Curello S, de la Torre Hernandez J, De Servi S, Belloni F, Windecker S, Penzo C, Colombo A, da Costa B, Frigoli E, Palmieri C, Nazzaro M, Falcone C, Liso A, Vigna C, Abate F, Comeglio M, Diletti R, Gabrielli G, Di Lorenzo E, Mazzarotto P, Zimarino M, Moretti C, Valgimigli M

June 12, 2019 | 10.4244/EIJ-D-18-00247

Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis

Collet J, Kerneis M, Lattuca B, Yan Y, Cayla G, Silvain J, Lapostolle F, Ecollan P, Diallo A, Vicaut E, Hamm C, van 't Hof A, Montalescot G

September 20, 2018 | 10.4244/EIJ-D-18-00182

One-year clinical outcome of early administration of intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary reperfusion

Roolvink V, Ottervanger J, Ibáñez B, Dambrink J, Gosselink M, Kedhi E, van Royen N, Lipsic E, Remkes W, Piek J, Fuster V, van 't Hof A

August 24, 2018 | 10.4244/EIJ-D-17-00776

Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial

Fabris E, van 't Hof A, Hamm C, Lapostolle F, Lassen JF, Goodman S, ten Berg JM, Bolognese L, Cequier A, Chettibi M, Hammett C, Huber K, Janzon M, Merkely B, Storey R, Zeymer U, Cantor WJ, Rousseau H, Vicaut E, Montalescot G

May 15, 2017 | 10.4244/EIJ-D-16-00965

Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: three-year results of the XAMI trial

Hofma S, Smits PC, Brouwer J, Velders M, van 't Hof A, Quere M, de Vries C, Van Boven A

March 20, 2015 | 10.4244/EIJY15M01_03

Early or late intervention in high-risk non-ST-elevation acute coronary syndromes: results of the ELISA-3 trial

Badings E, The S, Dambrink J, van Wijngaarden J, Tjeerdsma G, Rasoul S, Timmer J, van der Wielen M, Lok D, van 't Hof A

May 21, 2013 | 10.4244/EIJV9I1A9

De Luca G, Gibson CM, Huber K, Dudek D, Cutlip D, Zeymer U, Gyöngyösi M, Bellandi F, Noc M, Arntz H-R, Maioli M, Secco G, Zorman S, Gabriel H, Emre A, Rakowski T, van 't Hof A

August 24, 2012 | 10.4244/EIJV8I4A74

Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay

Heestermans A, de Boer M, van Werkum J, Mosterd A, Gosselink A, Dambrink J, van Houwelingen K, Koopmans P, Hamm C, Zijlstra F, ten Berg JM, van 't Hof A

August 30, 2011 | 10.4244/EIJV7I4A73

Triggering mechanisms of stent thrombosis

Zwart B, van Werkum J, Heestermans A, Kelder J, Zomer A, van 't Hof A, Verheugt F, ten Berg JM

January 20, 2011

Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial

Timmer J, ten Berg JM, Heestermans A, Dill T, van Werkum J, Dambrink J, Suryapranata H, Ottervanger J, Hamm C, van 't Hof A

August 15, 2010

Incidence, predictors and prognostic importance of bleeding after primary PCI for ST-elevation myocardial infarction

de Boer M, Hoorntje J, Gosselink A, Suryapranata H, van 't Hof A

May 25, 2010

Non-culprit lesions detected during primary PCI: treat invasively or follow the guidelines?

Dambrink J, Debrauwere J, van 't Hof A, Ottervanger J, Gosselink M, Hoorntje J, de Boer M, Suryapranata H

April 12, 2010

How to set up an effective national primary angioplasty network: lessons learned from five European countries

Knot J, Widimský P, Wijns W, Stenestrand U, Kristensen S, van 't Hof A, Weidinger F, Janzon M, Nørgaard B, Soerensen J, van de Wetering H, Thygesen K, Bergsten P, Digerfeldt C, Potgieter A, Tomer N, Fajadet J

August 14, 2009

Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design

van 't Hof A, Hamm C, Rasoul S, Gupthan S, Paolini J, ten Berg J

November 20, 2007

Arnoud van 't Hof

Latest news